Crystal form of ozanimod, and preparation method and pharmaceutical composition thereof
AssigneeSolipharma LLC
InventorsXiaohong SHENG, Xiaoxia SHENG, Jianfeng ZHENG
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel crystal forms of ozanimod. Compared with the prior art, the crystal forms of the present invention have one or more improved properties. The present invention also relates to preparation methods of the crystal forms, pharmaceutical compositions thereof and uses thereof for the manufacture of medicament for treating and/or preventing diseases or adverse conditions associated with modulation, activation, stimulation, inhibition or antagonization of selective sphingosine-1-phosphate (S1P) receptor.
Claims18
Ozanimod Form 1, with the chemical structure shown in the following formula (I),
- characterized in that, the X-ray powder diffraction pattern of Form 1, expressed as 2θ angles, has the following characteristic peaks:
- 5.7±0.2°, 8.6±0.2°, 11.5±0.2°, 13.3±0.2°, 16.2±0.2° and 19.5±0.2°.
Ozanimod Form 2, with the chemical structure shown in the following formula (I),
- characterized in that, the X-ray powder diffraction pattern of Form 2, expressed as 2θ angles, has the following characteristic peaks:
- 4.2±0.2°, 16.0±0.2°, 23.4±0.2°, 26.7±0.2° and 30.3±0.2°.
Ozanimod Form 3, with the chemical structure shown in the following formula (I),
- characterized in that, the X-ray powder diffraction pattern of Form 3, expressed as 2θ angles, has the following characteristic peaks:
- 4.6±0.2°, 9.1±0.2°, 13.6±0.2°, 18.1±0.2° and 22.7±0.2°.
Dependencies are inferred from the claim text.